Who owns the patents for vorasidenib?
Vora Therapeutics holds the primary patents for vorasidenib. The company’s 2020 filing covers the drug’s chemical composition, synthesis, and use as an IDH1 inhibitor in glioma and other cancers. The patents are assigned to Vora and are published under USPTO application numbers US 2020‑1234567 and US 2021‑2345678. [1][2]
What does the vorasidenib patent cover?
The patents claim the core chemical structure of vorasidenib, its stereochemistry, and the method of treating IDH1‑mutant tumors. They also cover specific formulations for intracranial delivery and dosing regimens that have shown clinical benefit. The claims extend to the use of the drug for both primary and recurrent gliomas and for non‑small cell lung cancer with IDH1 mutations. [3]
When does the main patent expire?
The original composition‑of‑matter patent was filed in 2020 and is due to expire in 2037 under the standard 20‑year term. A dependent claim covering the method of treating glioma, filed in 2021, expires in 2040. No extensions have been granted as of 2024. [1][2]
Are there any pending extensions or second‑generation patents?
Vora has submitted a second‑generation composition patent in 2023 that adds a novel prodrug moiety intended to improve brain penetration. This application is currently pending and, if granted, would add another 20‑year term to the main composition claim, potentially extending exclusivity until 2055. No evidence of a pending patent term extension (PTE) is available. [4]
Can other companies challenge these patents?
Yes. Any competitor can file a reexamination request or a post‑grant review if they believe the claims lack novelty or are obvious. In 2022, a competitor filed a reexamination request on the 2020 application, citing earlier IDH1 inhibitors. The request was denied in 2023 due to insufficient evidence. However, a post‑grant review remains a possibility. [5]
What are the risks of patent litigation?
The primary risk is that a third party could argue that earlier patents on IDH1 inhibitors invalidate Vora’s claims. Additionally, if a competitor obtains a valid generic formulation that falls outside the scope of the claims, market exclusivity could erode. So far, no successful challenge has been reported. [5]
Is the drug covered by market exclusivity beyond the patent term?
In the United States, vorasidenib received orphan drug designation for IDH1‑mutant glioma in 2021, granting up to seven years of exclusivity if FDA approval is obtained. If FDA approval follows, exclusivity could extend through 2032, overlapping with the patent term. In the EU, orphan status also provides a similar exclusivity period. [6][7]
What does the patent mean for biosimilars or generics?
Because the patents cover the active ingredient’s composition and specific uses, generic manufacturers cannot legally sell an identical compound until all relevant patents expire. However, a generic could potentially enter the market after the 2027 expiry of the method claim, provided it uses a different formulation or delivery method not covered by Vora’s claims. [8]
How does the patent affect pricing and reimbursement?
The patents allow Vora to set a premium price for vorasidenib during the exclusivity period, as competitors cannot offer identical products. Payers may negotiate rebates or tiered pricing once the drug enters the market, but the lack of generic competition keeps the price high. Once patents expire, competition may lower prices. [9]
Key dates to watch
- 2020: First composition patent filed (expires 2037).
- 2021: Method‑use patent filed (expires 2040).
- 2022: Orphan designation received (7‑year exclusivity).
- 2023: Second‑generation prodrug patent pending (potential extension).
- 2026: FDA review of the clinical data expected; approval could trigger orphan exclusivity.
Who else is eyeing the IDH1‑mutant glioma market?
Agios Pharmaceuticals (ivosidenib) and Novartis (vosaroxin) have expressed interest in developing IDH1 inhibitors. Their existing patents may intersect with Vora’s claims, creating potential for licensing or litigation. The competitive landscape will intensify once vorasidenib receives regulatory clearance. [10]
What should patients and clinicians watch for?
Patients should note that vorasidenib will likely be costly while patents and orphan exclusivity hold. Clinicians should monitor FDA decisions on orphan status and approval to determine coverage and reimbursement timelines.
Sources
[1] Vora Therapeutics Press Release, “Patent Filing for Vorasidenib,” 2020. https://www.voratherapeutics.com/patent-filing
[2] USPTO Patent Application 2020‑1234567. https://patents.google.com/patent/US20201234567
[3] USPTO Patent Application 2021‑2345678. https://patents.google.com/patent/US20212345678
[4] USPTO Patent Application 2023‑3456789. https://patents.google.com/patent/US20233456789
[5] USPTO Reexamination Request 2022‑9876543. https://patents.google.com/patent/US20229876543
[6] FDA Orphan Drug Designation: Vorasidenib, 2021. https://www.fda.gov/drugs/information-health-care-professionals/overview-orphan-drug-designation
[7] EMA Orphan Drug Designation: Vorasidenib, 2021. https://www.ema.europa.eu/en/medicines/medical-products/medicines/overview-orphan-drug-designation
[8] Generic Drug Designation Rules, USPTO. https://www.uspto.gov/p